No Data
Corcept Therapeutics Announces Results From CATALYST Clinical Trial At ADA's 84th Scientific Sessions; Study Shows 24% Prevalence Of Hypercortisolism In Patients With Difficult-To-Control Type 2 Diabetes; Largest Study To Date With 1,055 Patients
Results from the CATALYST clinical trial were presented at the American Diabetes Association's 84th Scientific Sessions at a featured plenary session titled: "Prevalence of Hypercortisolism in Difficu
Express News | Corcept Therapeutics Inc - Results Demonstrate a Hypercortisolism Prevalence Rate of 24 Percent in This Patient Population
Express News | Corcept Announces Presentation of Results From Prevalence Phase of Catalyst Clinical Trial at American Diabetes Association’s Scientific Sessions
What Makes Corcept Therapeutics (CORT) a Good Investment Bet?
6 Analysts Have This To Say About Corcept Therapeutics
During the last three months, 6 analysts shared their evaluations of Corcept Therapeutics (NASDAQ:CORT), revealing diverse outlooks from bullish to bearish.The table below provides a snapshot of their
Corcept Therapeutics Price Target Maintained With a $65.00/Share by Truist Securities
Corcept Therapeutics Price Target Maintained With a $65.00/Share by Truist Securities